Amylin will be introducing data through over 20 posters and eight oral presentations at the meeting. The data will demonstrate significant progress in key research and clinical programs that include studies of BYETTA, SYMLIN, and Amylin's early and late-stage pipeline candidates... Amylin's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
June
(29)
- KineMed and Daiichi Sankyo : New Discovery of Key ...
- Tranzyme Pharma to Present “Ghrelin Agonist (TZP-1...
- Speedel : SPP100 (TEKTURNA/RASILEZ) DEMONSTRATES P...
- Novo Nordisk and Sciele Pharma : FDA Approves Pran...
- SurModics : Initiation by Merck & Co., Inc. of Ph...
- OSI Pharmaceuticals : Diabetes/Obesity Preclinical...
- Osiris Therapeutics : $2 Million Milestone Payment...
- Melior : Option Agreement with Pfizer
- Nastech : Positive Intranasal Insulin Data at Amer...
- CytRx : Favorable Study Data with Iroxanadine in D...
- AVANIR : Grant of New Zenvia Patent
- Tethys Bioscience : Expanded Availability of PreDx...
- Antigen Express and Generex Biotechnology : Blood ...
- Roche : investigational diabetes drug, Taspoglutid...
- LCT : Diabetes Clinical Trial
- VeraLight Plans FDA Submission of Non-invasive Dia...
- VistaGen Licenses Customized Stem Cell-Based Drug ...
- Sanofi-aventis : Acomplia (rimonabant) significant...
- LifeScan and ResMed : Co-Marketing Agreement Focus...
- AstraZeneca & Bristol-Myers Squibb : ONGLYZA™ (s...
- MDS Pharma : Therapeutic Focus Metabolic Disorders
- Amylin Pharmaceuticals : Promising Data From Diabe...
- Novo Nordisk files for regulatory approval of lira...
- MacroChem : Presentation by Michael Zasloff, MD, P...
- Merck : New Data Released at Major Diabetes Meetin...
- Amylin, Lilly and Alkermes : Type 2 Diabetes Pat...
- Takeda : Voglibose (BASEN) for the prevention of t...
- Amylin and Lilly : Monotherapy BYETTA (exenatide) ...
- sanofi-aventis : Study Shows LANTUS Helped People ...
-
▼
June
(29)
Sunday, June 8, 2008
Amylin Pharmaceuticals : Promising Data From Diabetes and Obesity Programs at ADA 2008
June 2, 2008, 2008 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that the company will present new data for its FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline diabetes and obesity drug candidates at the American Diabetes Association's 68th Annual Scientific Sessions (ADA) being held in San Francisco, CA from June 6 to 10. The company will also host an investor presentation on Sunday, June 8, at 7:45 PM PT (10:45 PM ET) that will be available by webcast. ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and the delivery of diabetes care.